Spun off from the accelerator NuXcel, ShiraTronics is a med-tech startup working on migraine headache treatment.
The Minneapolis medical device maker has received federal premarket approval for what it claims is the world’s first heart failure neuromodulation device.
The new Motion Medical will accelerate the development of medical technology and new minimally invasive treatments for “unmet medical needs.”
The Republican politician, who lost his House seat to Dean Phillips in the 2018 election, replaces a retiring member of the board of directors of the St. Paul-based medtech company.
Two years after merging with a German competitor to form the world’s largest healthcare sterilization product supply company, Key Surgical has acquired German wholesaler Insitumed GmbH.
Acquisitions by UnitedHealth Group and 3M made up the bulk of M&A activity.
The transaction is aimed at building Agiliti’s presence in the clinical engineering space.
The spinoff enables Miromatrix to focus on its long-term goal of developing transplantable livers and kidneys from regenerated pig tissue.
In its fifth and largest funding round yet, the company has raised $13.8 million from 48 investors.
The new healthcare record-keeping company will be named Datica, and Sansoro’s CEO will lead it out of Minneapolis.
The flaw could make the devices vulnerable to hackers, according to the company.
The acquisition builds Minneapolis-based Bio-Techne’s cell and gene therapy product portfolio, and marks its 15th acquisition in five years.
Epstein brings more than 30 years of leadership experience in the medtech industry.
Pharmaceutical company plans expansion to Maple Grove campus as Minnesota's pharma biotech sector continues to grow
Medtronic rebuffs a claim that the FDA allowed the company to hide reports of issues with its Sprint Fidelis defibrillator—recalled in 2007.
Feds say they'll fast-track review of NightWare Inc.’s nightmare-curbing app.
The estimated $4.3 billion deal, considered 3M’s largest ever, will improve 3M’s presence in the medical device space—the only area that saw sales growth in Q1.
Breathe99 is developing a high-tech breathing mask that offers protection—and looks cool.
Company won 2018 Tekne Award in medical device category.
After obtaining FDA approval in November, the five-year-old company is bringing to market its Pops! One system, which boasts a virtual care approach that’s less invasive than other offerings.
The capital will go partly toward a U.S. clinical trial for Nuvaira’s Lung Denervation System, a new market-alternative treatment of cardiovascular obstructive pulmonary disease.
In addition to debuting the MyCareLink Heart app this week, Medtronic also enrolled its first patient for a new study examining an alternative, safer solution to oral opioids for back pain treatment.
The Stillwater-based startup, Vascudyne Inc., will move to commercialize two cardiovascular-related products that utilize its novel technology: living replacement tissue made of skin cells.
The startup focuses on personalizing chronic disease treatment, and will use the investment money to commercialize a new blood-based test for obesity types in 2019.
The St. Louis Park-based company’s products treat mitral valve regurgitation, a common heart malfunction experienced by Americans.
At the age of 94, Columbia Heights native Earl Bakken passed away on Sunday. Many on Monday are remembering him for his positive (and oftentimes life-saving) contributions.
Former Medtronic CEO Bill George, Medical Alley Association Shaye Mandle, and David Rhees, the retired director of The Bakken Museum, offer up their thoughts on Earl Bakken.
Combining RetiSpec’s machine learning program with the U of M’s imaging system is expected to accelerate time-to-market for a groundbreaking Alzheimer’s detection tool.
The Minneapolis-based medtech startup’s lifetime financing now tops $30 million.
The new capital will allow the Brooklyn Park heart therapies maker to hire up to ten new workers, expand into a larger headquarters, and fund new rounds of further testing of its AltaValve device.